Pharmatest establishes new US subsidiary
Press Release | Pharmatest Services Ltd
JUNE 16, 2017
Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services Ltd (Pharmatest) has established a new operating subsidiary for the USA, Pharmatest Services LLC.
Pharmatest Services LLC (the LLC) will be a CRO based in Massachusetts, offering preclinical efficacy services in oncology and skeletal diseases across the USA. The company is a fully owned subsidiary of Pharmatest Services Ltd based in Finland.
Oncology and skeletal disease models
In skeletal diseases Pharmatest offers models of osteoporosis and osteoarthritis. In oncology Pharmatest has special expertise in clinically predictive orthotropic and metastasis models, and Pharmatest has been the global leading provider of models of bone metastasis since 2007. As bone experts Pharmatest also offers bone safety studies.
Jussi Halleen, CEO of Pharmatest commented: “Our US sales have grown more than 50 per cent per year over the past few years. We expect this growth to continue in coming years, and we established the LLC to be able to better serve our US customers. When the business grows it is our long-term goal to offer more jobs for skilled people in the US.”
Preclinical bone metastasis seminar
Andrew Heiniluoma is the manager of the LLC, who will lead its operations. He says: “I am thrilled to see how the expertise and high quality preclinical services of Pharmatest will help American drug development companies to save time, money and effort, and at the same time develop compounds that are more effective in the clinic.”
Pharmatest Services LLC is inviting life sciences professionals to join an expert panel for an educational seminar about the importance of preclinical bone metastasis studies, to be held in Boston on September 6, 2017.The event will be co-hosted with Taconic Biosciences. More detailed information about the event will be available later.
Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.
Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.
Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.
The CRO has supported more than 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.
Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.
Jussi Halleen; CEO, Pharmatest Services Ltd.
Tel.: + 358 50 380 9551